Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02464046 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity
A Phase 2 study of Insomnia, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 5
- Study locations
NCT02464046 is a Phase 2 study of Insomnia that has completed, run by Janssen Research & Development. The registered enrollment target is 28 participants, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (84% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT02464046, a Phase 2 study of Insomnia, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary purpose of this study is to investigate the effect of JNJ-42847922 (change versus placebo) on sleep efficiency (SE) measured by polysomnography (PSG) after single and multiple dose administration to participants with insomnia disorder without psychiatric comorbidity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-42847922
Study Locations (5)
Other
- - Berlin
- - Hamburg
- - Schwerin
- - Leiden
Florida
- - Hollywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-07-27 |
| Est. Completion | 2015-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02464046
The ClinicalTrials.gov registry entry for NCT02464046 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (84% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02464046 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Other, Florida.
Frequently Asked Questions
What is clinical trial NCT02464046 about?
NCT02464046 is a clinical study titled "Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity". The primary purpose of this study is to investigate the effect of JNJ-42847922 (change versus placebo) on sleep efficiency (SE) measured by polysomnography (PSG) after single and multiple dose administration to participants with insomnia disorder without psychiatric comorbidity.
What is the current status of trial NCT02464046?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2015-07-27. Estimated completion is 2015-12-02.
What conditions does trial NCT02464046 study?
This clinical trial studies the following conditions: Insomnia.
What interventions are being tested in trial NCT02464046?
The interventions under investigation include: Placebo (DRUG), JNJ-42847922 (DRUG).
Who is sponsoring clinical trial NCT02464046?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02464046 being conducted?
This trial has 5 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Pimavanserin for Insomnia in Veterans With PTSD
RECRUITING · Phase 2
-
Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse
RECRUITING · Phase 2
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
Suvorexant for Treatment of AUD and PTSD
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.